Pfizer Ventures, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. Pfizer Ventures seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.

HOW WE WORK

- Active investor, working with management to develop product strategy and build shareholder value.
- Bring Pfizer pedigree and perspective to our portfolio companies, providing the ability to utilize the network, expertise and resources of Pfizer for their benefit.
- Potential for Pfizer business development relationship whenever appropriate.

With a $600M capital investment from Pfizer for private investments, Pfizer Ventures invests in private companies at all stages of development, with a strong focus on early stage opportunities. Other investments, including start-ups, spinouts and consortia opportunities, will also be considered. We actively work with our current portfolio companies throughout their growth cycles, contributing strategic guidance in addition to our capital and providing access to internal Pfizer expertise, whenever appropriate. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation commensurate with our investment.

For additional information, please visit our website www.pfizerventures.com
INVESTMENT STRATEGY

- Primarily focused on potentially transformative therapeutics, with an emphasis on Pfizer’s core therapeutic areas; Oncology, Rare Disease, Inflammation and Immunology, Internal Medicine and Vaccines.
- Focus also includes neuroscience investments, following Pfizer’s decision to continue advancing research in this critical area of unmet medical need through a venture capital strategy.
- Will also consider platform technologies, diagnostics, drug delivery, pharmaceutical services and other technologies that have the potential to transform drug discovery and development.

Geography
- U.S. focused
- Approximately 20% of investments may be outside U.S.

Investment Type
- Direct investing
- All stages possible, with focus on early stage

Returns
- Strategic and financial
- Measured over long term

Funding
- $600M capital commitment from Pfizer
- Up to $10M in first investment; reserved allocation for follow-on investments

Syndication
- Invest as member of a syndicate, lead where appropriate
- Syndicate member located near company critical

Collaboration
- Potential for business relationship with Pfizer considered in investment criteria
- Can be transacted in parallel with investment or explored in the future

Influence in Development
- Contribute capital and industry experience to help guide development and company growth
- Scientific advisory board participation desired

Control
- Minority ownership positions
- Board seats where appropriate

Deal Structure
- Traditional VC investment
- Product rights not required

ACTIVE PORTFOLIO COMPANIES

4D Molecular Therapeutics
Emeryville, CA
4dmoleculartherapeutics.com

Accelerator Corporation
New York, NY
acceleratorcorp.com

Adapsyn Bioscience
Hamilton, Canada
adapsyn.com

AMRA
Linköping, Sweden
amra.se

AnToIrx
Cambridge, MA
antoirx.com

Aquinnah Pharmaceuticals
Cambridge, MA
aquinnapharma.com

Arkuda Therapeutics
Cambridge, MA
arkudatx.com

Arrakis Therapeutics
Waltham, MA
arrakistx.com

Artios Pharma
Cambridge, UK
artiospharma.com

Autifony Therapeutics
London, UK
autifony.com

BioAtla
San Diego, CA
bioatla.com

Biodesy
South San Francisco, CA
biodesy.com

Blade Therapeutics
South San Francisco, CA
blademed.com

Complexa, Inc.
Berwyn, PA
complexa.com

Cortexyme
South San Francisco, CA
cortexyme.com

Cydan II, Inc.
Boston, MA
cydanco.com

eFFECTOR Therapeutics
San Diego, CA
effector.com

Epic Sciences
La Jolla, CA
epicsciences.com

FoRx Therapeutics
Basel, Switzerland

G-CON Manufacturing
Bryan, TX
gconbio.com

Imara
Cambridge, MA
imaratx.com

ImCheck Therapeutics
Marseille, France
imchecktherapeutics.com

ImmunOs Therapeutics
Schlieren, Switzerland
immunosotherapeutics.com

Ixchelsis Limited
Sandwich, UK
ixchelsis.com

Jnana Therapeutics
Boston, MA
jnanax.com

Kymera Therapeutics
Cambridge, MA
kymeratx.com

Lodo Therapeutics
New York, NY
lodotherapeutics.com

Magna Neurosciences
New York, NY
magnanurosciences.com

Metabomed
Yavne, Israel
metabomed.com

MISSION Therapeutics
Cambridge, UK
missiontherapeutics.com

Mitokinin
San Francisco, CA
mitokinin.com

Morphic Therapeutic
Waltham, MA
morphictx.com

NeuMoDx Molecular
Ann Arbor, MI
neumodx.com

NextCure
Beltsville, MD
nextcure.com

Nimbus Therapeutics
Cambridge, MA
nimbushtx.com

Palleon Pharma
Waltham, MA
palleonpharma.com

Petra Pharma
New York, NY
petrapharmacorp.com

RefleXion Medical
Hayward, CA
reflexionmedical.com

Rhythm Pharmaceuticals
Boston, MA
rhythmx.com

Second Genome
San Francisco, CA
secondgenome.com

Simcha Therapeutics
New Haven, CT

Storm Therapeutics
Cambridge, England
stormtherapeutics.com

Strata Oncology
Ann Arbor, MI
strataoncology.com

System1 Biosciences
San Francisco, CA
system1.bio

Trex Bio
Burlingame, MA

Triplet Therapeutics
Cambridge, MA
triplettx.com

Yumanity Therapeutics
Cambridge, MA
yumanity.com

Portfolio as of January 3, 2020